Janux Therapeutics, Inc. (NASDAQ:JANX) Holdings Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 532.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 165,737 shares of the company's stock after purchasing an additional 139,543 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.32% of Janux Therapeutics worth $8,874,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the period. Rhumbline Advisers boosted its stake in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after buying an additional 599 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock worth $681,000 after buying an additional 928 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after buying an additional 949 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after purchasing an additional 1,095 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Performance

NASDAQ JANX traded up $1.21 during mid-day trading on Monday, reaching $25.01. 853,655 shares of the stock were exchanged, compared to its average volume of 884,360. The business's 50 day moving average is $27.37 and its 200-day moving average is $38.49. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71. The company has a market capitalization of $1.48 billion, a P/E ratio of -21.38 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JANX has been the topic of several recent research reports. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush restated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $95.25.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67% increase in their position. The disclosure for this purchase can be found here. 8.10% of the stock is currently owned by company insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.